MetaCap

Adaptive Biotechnologies (ADPT) vs Denali Therapeutics (DNLI)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Adaptive Biotechnologies (ADPT) has outperformed Denali Therapeutics (DNLI) over the past year, gaining 50.1% versus a gain of 2.5%. Over five years, ADPT leads with a -0.7% price change compared with -59.0% for DNLI. Adaptive Biotechnologies is the larger company by market cap ($4.52 billion vs $2.96 billion), about 1.5 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ADPT+50.08%DNLI+2.50%
+67%+15%-38%
Nov 21, 20251 yearNov 20, 2026
ADPT+2.12%DNLI-60.84%
+13%-42%-96%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ADPT versus DNLI key metrics
MetricADPTDNLI
Share price$27.93$18.45
Market cap$4.52B$2.96B
1-day change-0.43%+1.37%
YTD return+71.98%+11.75%
1-year return+50.08%+2.50%
5-year return-0.68%-59.02%
EPS (TTM)$-0.45$-1.72
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)$276.98M$0
Revenue growth (YoY)+54.77%—
Net income (latest FY)$-59.50M$-512.54M
Gross margin74.24%—
Operating margin-20.62%—
Net margin-21.48%—
52-week high$32.21$27.30
52-week low$12.00$15.34
Distance from 52-week high-13.29%-32.42%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+21.23%+94.15%
Average volume2.20M1.68M
Shares outstanding161.88M160.29M
Employees624503
SectorHealth CareHealth Care
IndustryBiotechnology: Biological Products (No Diagnostic Substances)Biotechnology: Biological Products (No Diagnostic Substances)

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ADPT has outperformed DNLI by 47.6 percentage points over the past year.

About Adaptive Biotechnologies

ADPT stock →

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system.

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 624 employees

About Denali Therapeutics

DNLI stock →

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome).

Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 503 employees

ADPT vs DNLI FAQ

Which is bigger, Adaptive Biotechnologies or Denali Therapeutics?

Adaptive Biotechnologies (ADPT) is larger, with a market capitalization of $4.52B compared with $2.96B for Denali Therapeutics (DNLI).

Which stock has performed better over the past year, ADPT or DNLI?

ADPT returned +50.08% over the past 12 months, compared with +2.50% for DNLI (price return, excluding dividends). Past performance does not predict future results.

Are Adaptive Biotechnologies and Denali Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.

More comparisons